Focus

NA Semax Amidate.

Available Variants

30 mg

View lab reports Quality process

Research area: Focus

🛡️

For research purposes only. Not intended for use in humans or animals.

Neuroscience research

About NA Semax Amidate

NA Semax Amidate is studied in the context of neuroscience and cognitive research. The presumed mechanism is inferred from the parent-compound Semax literature (including modulation of BDNF/TrkB expression), but has not been independently confirmed for this amidated/acetylated variant itself.

Research Application

Marketed by suppliers as a more stable, longer-acting Semax variant for neurotrophic research; independent efficacy or pharmacokinetic data for this specific variant do not exist.

Important to know

Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.

Content 30 mg

Form Lyophilized powder

Category Focus

Purity & Identity see lab reports →

Sequence / Structure N-acetylated, C-terminally amidated analog of the heptapeptide Semax (an ACTH(4-10) fragment derivative).

Regulatory Status Not an approved drug; no independently published pharmacological study of this amidated variant itself was found — sold only as a research chemical by peptide vendors. The underlying stabilization strategy (N-acetylation plus C-terminal amidation) is known from the Semax/Selank research line.

Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.

Research Overview

Studies on neuroscience-related peptides are predominantly preclinical.

Specific study references will be added for this product. For current literature, independent research (e.g. via PubMed) is recommended.

Similar Peptides

Focus Semax View → Focus Semax / Selank Mix View → Focus NA Selank Amidate View → Focus Selank View →

Question about NA Semax Amidate?

We reply personally – via email or Telegram.

✉️ Email ✈️ Telegram

← Back to overview